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Abstract: Tobacco smoking is a growing problem throughout Latin American countries, 
especially in underdeveloped countries where poverty and lack of education about the dangers 
of smoking may make people more susceptible to becoming smokers. Moreover, the econo-
mies of many Latin American countries have become dependent on the production of tobacco. 
Furthermore, because of the associated promotion of tobacco, smoking has integrated into 
many Latin American cultures. Nevertheless, the harmful health effects of tobacco use are well 
documented, including greatly increased risks of developing chronic obstructive pulmonary 
disease, cardiovascular disease, and many forms of cancer. The medical costs associated with 
treating these diseases far outweigh the economic beneﬁ  ts of producing and selling this deadly 
crop. To control the tobacco pandemic in Latin American countries, nicotine addiction must 
be recognized and treated as a disease. Governments, both national and local, need to be more 
involved in enacting anti-smoking policies such as higher tobacco taxation, control of illegal 
tobacco smuggling, and reimbursement of medical smoking cessation interventions. The train-
ing of health professions in the area of nicotine addiction must also be improved, so that they 
may better assist smokers in their quit attempts and advise patients on, and prescribe, effective 
smoking cessation pharmacotherapies.
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Introduction
In only 6 centuries, the production and consumption of tobacco has been extended 
from the Americas to the rest of the world without respecting borders, cultures, or 
beliefs. During this period, tobacco consumption integrated naturally into different 
societies, such that about 80% of certain sectors of these populations have at least 
tried smoking (Zabert and Verra 2004; Müller and Zabert 2005).
Tobacco consumption is one of the greater pandemics of all time. Active smoking 
puts a patient at greater risk for developing chronic obstructive pulmonary disease 
(COPD) than any other single risk factor (USDH 1984, 1986, 1990). Of all the cases 
of COPD worldwide, 81.5%–90.0% can be attributed to a history of smoking (USDH 
1984, 1986, 1990). COPD is often accompanied by other smoking-related comorbidi-
ties such as cancer, cardiovascular disease (CVD), and stroke (USDH 1990; Mackay 
et al 2006). Other chronic diseases such as osteoporosis are also prevalent in patients 
with COPD (Biskobing 2002). In addition, COPD has been linked to increased rela-
tive risk of hospitalization for and mortality from CVD (Huiart et al 2005; Sidney 
et al 2005), especially in patients under 65 years of age (Sidney et al 2005). Between 
COPD and other smoking-related diseases (eg, cancer and cardiovascular disease), 
smoking will eventually kill half of the current 1.25 billion smokers in the world 
(WHO 2002). Currently, smoking causes 5 million deaths annually (www.paho.org) International Journal of COPD 2008:3(2) 286
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and these death tolls are predicted to reach 1 billion people 
in the next century (Mackay et al 2006). These numbers 
will not be equally distributed throughout the entire world. 
Developed countries will experience 50% increases in 
tobacco-related deaths, whereas underdeveloped countries 
will see smoking-related deaths increase by 700% (Crofton 
1990; Mackay et al 2006). By 2030, tobacco consumption 
will kill up to 10 million people every year (Organización 
Mundial de la Salud 2000), and 70% of those deaths will 
occur in developing countries (Organización Mundial de 
la Salud 1999). Poverty and lack of education (Medina and 
Kaempffer 1991; Harwood et al 2007), and promotion of 
smoking in women (Jacobson et al 1989) and adolescents 
(Granero and Sanchez 2006) are key factors contributing to 
the exponential growth of the tobacco pandemic.
When faced with these issues, a few questions prevail. 
What makes tobacco consumption a universal phenomenon 
without geographic, idiomatic, or cultural limits? How, 
in only a few centuries, did tobacco consumption spread 
throughout the entire world from Latin America? Why does 
this pandemic continue to remain ignored, diminished, and 
disqualiﬁ  ed, in spite of considerable evidence from more 
than a half century of research about the harmful effects of 
tobacco?
Tobacco production
The 2nd edtion of The Tobacco Atlas lists 20 Latin American 
countries that seed and cultivate tobacco (Table 1) (Mackay 
et al 2006). Currently, 5 out of the 25 largest tobacco pro-
ducers in the world are countries of this region (Brazil, 
Argentina, Cuba, Dominican Republic, and Colombia) 
(Valdés-Salgado et al 2002). Brazil stands out as the second 
largest worldwide producer of tobacco, generating 928,300 
tonnes annually, and as the top tobacco exporter (US$1,052 
million during 2003) (Mackay et al 2006). At the time of the 
data used in the 2nd edition of The Tobacco Atlas, Argen-
tina was the eighth largest worldwide producer (118,000 
tonnes/year) (Mackay et al 2006). Now with a production 
of 161,000 tonnes/year (2006), however, it would occupy 
ﬁ  fth place among the countries listed in The Tobacco Atlas. 
Overall in Latin America, tobacco production between 1995 
and 2000 grew 29.5%. During the same period, the amount 
of land used to cultivate tobacco increased by 10.3% and 
the yields per hectare improved by 17.3% (Valdés-Salgado 
et al 2002).
These data underscore the economic impact of tobacco 
production in Latin America, which presents a challenge 
for the next generations who will have to promote other 
strategies to break free from the economic dependence on 
tobacco (eg, substitution of plantations).
Tobacco pricing
Local economies determine how individual countries and 
tobacco producers price cigarettes. This is why, for example, 
Venezuela and Paraguay have the lowest worldwide prices of 
premium cigarettes like Marlboro (less than US$1 for a pack 
of 20) (Mackay et al 2006). In Argentina, Brazil, Peru, Ecua-
dor, Colombia, Mexico, Costa Rica, Panama, and Guatemala, 
prices oscillate between US$1 and US$1.99. In Chile, and 
Uruguay the cost varies from US$2 to US$2.9 (Mackay et al 
2006). In addition, alternative brands of cigarettes may sell 
at much lower prices, such as in Argentina, where the prices 
of these cheap brands do not surpass US70 cents.
These low prices, in conjunction with underdeveloped 
conditions of much of Latin America, foster more tobacco 
consumption and constantly increase the total number of 
smokers, especially among adolescents and women (Mackay 
et al 2006). Furthermore, tobacco production is not associ-
ated with a higher index of wellbeing. The major tobacco-
producing provinces in Argentina, for example, show the 
smallest index of human development, the biggest percent-
age of insufﬁ  cient basic needs, the highest illiteracy rate of 
the country, and the shortest life expectancy (Ministerio de 
salud-OPS 2006). The losses generated by smoking-related 
Table 1 Tobacco cultivation in Latin America
Country Hectares  Tonnes
Argentina 66,000  118,000
Bolivia 1,060  100
Brazil 469,678  928,300
Chile 2,970  9,300
Colombia 13,000  28,000
Costa Rica  117  200
Cuba 33,942  34,500
Ecuador 4,300  8,000
El Salvador  600  1,100
Guatemala 9,232  20,500
Haiti 450  500
Honduras 1,170  5,200
México 11,461  21,900
Nicaragua 1,395  2,200
Panama 1,250  2,300
Paraguay 8,268  16,500
Peru 1,050  12,200
Dominican Republic  14,000  18,000
Uruguay 900  3,000
Venezuela 3,246  6,100
Total 644,089  1,235,900
644,089 hectares in Latin America are destined to seedtime, reaching a production of   
1,235,900 tonnes per year. Data derived from the 2006 Tobacco Atlas (Mackay et al 2006).International Journal of COPD 2008:3(2) 287
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diseases widely surpass the economic gains that the industry 
produces.
As of 2003, Argentina spends US$1.4 million annually 
on the treatment of tobacco-related pathologies (Bruni 
Informe ﬁ  nal 2004). This represents 15.5% of the total health 
care costs and these costs were not compensated by revenues 
from tobacco taxes (ie, US$806 million in 2003) (Ministerio 
de Salud y Ambiente de la Nación 2005a). In Colombia, 
the losses from tobacco-related premature mortality and 
disease-related disability are 4 times greater than the income 
generated by tobacco in the economy of the country (Perez 
and Wiesner 2004).
One strategy to wean countries of their economic depen-
dence on tobacco production would be to enact policies that 
raise the price of cigarettes. Not only would this increase 
the amount of taxes collected for each pack sold, but it 
may also reduce the prevalence of smoking (World Bank 
1999). A 10% rise in the price of a pack of cigarettes, in 
high income countries, has been linked to a potential 4% 
decrease in smoking and in low to middle income countries; 
this beneﬁ  t doubles to an 8% drop in smoking levels (World 
Bank 1999). Moreover, the effects of such a price increase 
is even more pronounced in adolescent smokers, with a 10% 
price increase yielding an estimated 14%–15% fall in smok-
ing (Ding 2003, 2005). However, for price increase to be an 
effective measure, illegal tobacco smuggling would need to 
be controlled.
Tobacco smuggling
In Latin America, tobacco smuggling is a serious problem 
(Joossens and Raw 1998). A considerable circuit of illegal 
trade exists from Aruba (Dutch Antilles) to many Carib-
bean ports and Colombia (Anon 1989). Also since 2002, 
the illegal pathway from Paraguay to Argentina has grown 
considerably and today comprises 20% of the whole tobacco 
market (Misdorp 1990). Although Paraguay exports 2 bil-
lion cigarettes legally each year, its actual production is near 
40 billion cigarettes. Since the country consumes 3 billion 
cigarettes a year, the ﬁ  nal destinations of 35 billion cigarettes 
is unknown (Misdorp 1990). Although in 2006, Uruguay 
Customs seized 24 million illegal cigarettes worth US$1 
million, most of those cigarettes had come from Argentina 
and Paraguay (Presidencia de la República Oriental del 
Uruguay. 2007). Of course, not all the illegal cigarettes in 
Uruguay come from other countries; in fact, 80% of the 
cigarettes produced in Uruguay for export return to the 
country to be sold illegally (Presidencia de la República 
Oriental del Uruguay 2007). Other Latin American countries 
also are exposed to illegal smuggled cigarettes. Data from 
the Finances Secretary of Brazil, for example, indicate that 
falsiﬁ  cation, illegal manufacturing, and smuggled products 
represented 30% of the total number of consumed cigarettes in 
2005 (Fish-Menezes 2006). Also, 14% of the cigarettes sold 
in Colombia in 2004 were counterfeit or smuggled (Anon 
2005a). Stronger measures throughout Latin America must be 
implemented to bring a halt to this illegal cigarette trade, not 
only to prevent the economic losses due to uncollected taxes, 
but also to prevent its people from being exposed to cheap, 
unregulated cigarettes that further encourage smoking.
Prevalence of tobacco consumption
Data linked to the incidence of tobacco consumption in the 
region are few, and frequently controversial. According 
to the 2nd ed of The Tobacco Atlas, the annual per person 
cigarette consumption in Latin American countries ranges 
between 500 and 1500 cigarettes per year (Mackay et al 
2006), with the exception of Ecuador, Peru, Bolivia, and 
Paraguay, where the annual per person cigarette consumption 
is less than 500 cigarettes per year (Shafey et al 2003; ERC 
Statistics International 2004; US Department of Agriculture, 
Foreign Agricultural Service 2004; Mackay et al 2006).
Between 8% and 10% of the smokers of the world (ie, 
more than 120 million) live in Latin America (Mackay et al 
2006), and thus, the smoking rates in Latin America are high 
(Table 2). Half of these smokers will die prematurely of a 
tobacco-dependent disease (WHO 2002).
Tobacco use among adolescents
Latin American data compiled from the Pan American Health 
Organization (PAHO) and the WHO show that 13.16% of 
young people between 15 and 18 years old are smokers 
(Organización Panamericana de la Salud 2005). The follow-
ing countries have the highest youth smoking rates of the 
region: Chile (39.2%), Colombia (33.4%), Mexico (27.1%), 
Argentina (25.8%), and Uruguay (22.9%). At the other 
extreme, Cuba (8.8%), Dominican Republic (5.8%), and 
Venezuela (8.4%) possess the lowest youth smoking rates of 
the region (Table 2) (Warren et al 2008). Although there are 
signiﬁ  cant variations between countryside (lower smoking 
prevalences) and urban zones (higher smoking prevalences), 
the rates vary between 20% and over 70%, showing that 
use of tobacco is a common behavior among young Latin 
American people (Department of Health and Human Ser-
vices, Centers for Disease Control and Prevention 2007). 
The addictive power of nicotine, the genetic predisposition 
of each “experimenter”, and other personal (ie, social and International Journal of COPD 2008:3(2) 288
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psychological) factors will inﬂ  uence how many of these 
young people become smokers in the long term.
Tobacco use among females
The incidence of tobacco consumption in adult women 
( 15 years) varies by Latin American region and usually 
the data differ according to the source researched. However, 
Latin America is a good example of the worldwide female 
trend of increasing tobacco addition (Table 2). A country that 
clearly exhibits this trend is Chile, with 34.9% of women being 
smokers in the 2005 survey (Organización Panamericana 
de la Salud 2005). The female smoking trends in Argentina 
(22.6%–30.7%), Bolivia (28.6%), Cuba (26.5%), Uruguay 
(25.1%), and Venezuela (23.3%) are also worrisome. The 
country with the smallest frequency of female adult smok-
ers is Guatemala with a rate of 0.9% on the 2005 survey 
(Organización Panamericana de la Salud 2005).
The numbers of females who are smokers are even more 
disquieting when analyzing the population of young women 
(15–18 years old) (Table 2). Colombia is the country with 
highest prevalence, reaching 31.0%, followed by Chile 
(27.5%), Ecuador (27.2%), Mexico (26.3%), and Nicaragua 
(25.6%). The lowest levels of tobacco consumption in this 
population are in Venezuela (6.0%), the Dominican Republic 
(7.3%), and Brazil (9.1%) (Warren et al 2008).
These data foretell a dire impact that tobacco-related 
diseases will have on the health of Latin American women, 
if smoking is not mediated with strong prevention measures 
and treatments against tobacco addiction. This is, and will 
continue to be, a big challenge for Latin America.
Strategies for change
The world is beginning to witness a great sociocultural 
change linked to tobacco. Nicotine addiction is more exten-
sive than ever in human history and its serious consequences 
are universally recognized. The tobacco pandemic has neces-
sitated a movement without precedent, in which nations from 
around the world must dictate policies to control its use and 
the consequences from it.
The WHO has warned about the dangers of tobacco and 
has been working for several years towards the establishment 
of changing strategies (World Health Organization 2007b). 
To this end, and after intense negotiations, 168 nations signed 
the Framework Convention on Tobacco Control (FCTC), 
which is the ﬁ  rst international health pact that establishes 
the basis of a synchronized and uniﬁ  ed ﬁ  ght of all of these 
countries against tobacco consumption (WHO 2007a). The 
FCTC has the objective “to protect present and future gen-
erations from the devastating health, social, environmental 
and economic consequences of tobacco consumption and 
Table 2 Prevalence of smoking in Latin America
Country Population†  Male (%)  Female (%)  Total (%)
Argentinaa 36,772,000  28.9  22.6  25.8
Boliviaa 8,814,000  31.0  28.6  29.9
Brazila 179,596,000  21.4  12.7  16.9
Chilea 15,774,000  39.0  34.9  37.0
Colombiab 44,584,000  26.8  11.3  18.9
Costa Ricaa 4,005,000  2.5  3.5  3.0
Cubaa 11,326,000  43.1  26.5  34.8
Dominican Republica 8,739,000  15.3  11.1  13.2
Ecuadora 13,008,000  7.9  1.9  4.8
El Salvadorc 6,533,000  42.1  14.8 N/Af
Guatemalaa 12,500,000  7.7  0.9  4.1
Haitid 8,440,000  10.7  8.6  9.5
Hondurasb 6,969,000  36.0  11.0  24.0
Mexicoa 102,291,000  12.5  4.5  8.3
Nicaraguae 5,480,000  32.9f 7.8  21.0f
Panamab 2,984,000  19.7  6.1  12.9
Paraguaya 5,643,000  23.6  7.4  15.5
Perub 27,148,000  52.5  17.8  33.8
Uruguaya 3,380,000  35.0  25.1  29.8
Venezuelaa 25,674,000  26.7  23.3  25.0
Data were collected from:
aThe PATIOS online database (Organización Panamericana de la Salud 2005).
b2nd edition of The Tobacco Atlas of the American Cancer Society (Mackay et al 2006).
cComisión Salvadoreña Antidrogas (Antidrug Commission of El Salvador) (Pan 
American Health Organization).
dNarcotics Awareness and Education Project (Haití: Developments Associates, Inc. 1991).
eCentral American Diabetes Initiative (Organización Panamericana de la Salud 2003).
fN/A, not available.
Table 3 Prevalence of smoking adolescents in Latin America
Country  Year  Boys (%)  Girls (%)  Total (%)
Argentina  2003  21.9 17.2 25.8
Bolivia  2003  16.3 20.3 12.0
Brazil 2005  12.3  9.1  12.9
Chile  2003  33.9 27.5 39.2
Colombia  2001  32.2 31.0 33.4
Costa  Rica  2002  16.4 15.7 16.8
Cuba  2004  10.0 11.2 8.8
Dominican  Republic  2004  6.6 7.3 5.8
Ecuador  2001  20.5 27.2 12.6
El  Salvador  2003  14.0 18.4 10.9
Guatemala  2002  14.3 17.3 11.2
Haiti  2005  17.6 17.2 17.7
Honduras  2003  14.2 14.4 14.1
Mexico  2005  27.1 26.3 27.1
Nicaragua  2003  21.2 25.6 17.4
Panama  2002  13.2 14.7 11.1
Paraguay  2003  19.1 19.2 18.5
Peru  2003  19.2 20.8 17.0
Uruguay  2007  20.2 16.4 22.9
Venezuela  1999  7.4 6.0 8.4
Data were derived from The Global Youth Tobacco Survey (Warren et al 2008).International Journal of COPD 2008:3(2) 289
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exposure to tobacco smoke by providing a framework for 
tobacco control measures to be implemented by the Parties 
at the national, regional and international levels in order 
to reduce continually and substantially the prevalence of 
tobacco use and exposure to tobacco smoke” (Molinari 
2006; WHO 2007a).
The FCTC took effect February 27, 2005, and since this 
date, it has been ratiﬁ  ed by 148 countries, including almost 
all the Latin American countries, with the exception of 
Argentina. In Argentina, the FCTC continues to be disputed 
by the Executive Power, which favors the FCTC, and the 
Legislative Power, where the representatives of the tobacco 
provinces refuse to accept the policies to the control tobacco. 
While each nation supporting the FCTC passes legislation 
to combat tobacco consumption, humanity as a whole must 
become aware of the magnitude of the problem. In Latin 
America, clinicians should make a serious effort to discour-
age smoking through patient education.
Role of health care professionals
One of the difﬁ  culties in controlling this epidemic is the lack 
of knowledge and training by doctors in treating tobacco 
addiction (Noble et al 1996; Zabert et al 1999; Minervini et al 
1998, 2006; Ferrero et al 2004). Each member of the health 
team has a fundamental role in the treatment. Nurses, social 
workers, administrators, directors, primary care physicians, 
and specialist doctors must know that tobacco consumption 
is a disease. All of them should promote an open atmosphere 
of a health treatment to compel people to stop smoking by 
advising and assisting in the treatment process with a level of 
intervention appropriate for each particular case (Ministerio 
de Salud y Ambiente de la Nación 2005b).
When reviewing information about tobacco addiction that 
medical students from 18 Latin America countries receive, 
the conclusion was that only 6 countries offer tobacco educa-
tion, 2 offer partial education, and 10 do not offer tobacco 
education at all (Table 4) (Organización Panamericana de 
la Salud 2005). In Argentina, for example, less than 30% of 
surveyed doctors acknowledged having received information 
on the subject (Rondelli et al 1999; Zabert et al 2002; Zabert 
and Verra 2004; Anon 2005b; Müller and Zabert 2005). Thus, 
the introduction of systematic education in tobacco consump-
tion at medical schools needs to be implemented to contribute 
to the cultural change of health professionals.
Doctors must position themselves to be leaders in the 
ﬁ  ght against tobacco. They must get involved and fulﬁ  ll their 
functions properly within their sphere of responsibilities. This 
is the model followed by countries that have experienced 
success in controlling the tobacco epidemic (Rondelli et al 
1999; Zabert et al 2002).
A lot of evidence indicates that health professionals who 
smoke are less active in the ﬁ  ght against tobacco consump-
tion. They may have less conﬁ  dence in their own advice; 
they may not believe in preventive intervention or in smok-
ing cessation; and they may even lack trust in the treatments 
against nicotine (Rondelli et al 1999; Anon 2005b; Müller 
and Zabert 2005). Another issue is that the frequency of 
tobacco consumption among Latin American health profes-
sionals is similar to the levels of the general population; 
only in Brazil and El Salvador are signiﬁ  cant differences 
observed, with indices up to ~7% (Mirra and Rosemberg 
1997b; Sánchez and Lisanti 2003; Bello et al 2004; Monreal 
et al 2004; Anon 2005b; Müller and Zabert 2005; Mackay 
et al 2006; Zabert 2006).
Initiating policies to control tobacco consumption – in 
conjunction with the availability of successful medical alter-
native treatments for nicotine addiction – will increase the 
demand for smoking cessation programs. For these reasons, 
education and training of health teams in general, and of 
doctors especially, is indispensable. These health profession-
als can, in turn, assist smokers using therapeutic resources 
with proven ability, without fear of discrediting themselves. 
Furthermore, smoking cessation clinics of trained health 
professionals could be established where doctors could refer 
smokers for additional support and treatment.
In this context, the tobacco cessation guidelines adapted 
to each country, and in particular to the Latin America 
Table 4 Tobacco education in medical schools
Country Year  Tobacco  education  Date
     received
Argentina  2002  In some universities  8/2002
Bolivia 2002  No  8/2002
Colombia 2002  No  9/2002
Ecuador 2002  No  7/2002
Peru 2002  Yes  7/2002
Venezuela 2002  No  8/2002
Costa Rica  2002  Yes  7/2002
El Salvador  2006  In some universities  1/2006
Guatemala 2002  No  7/2002
Honduras 2002  Yes  12/2002
Nicaragua 2002  No  8/2002
México 2002  Yes  8/2002
Brazil 2003  No  7/2003
Chile 2002  No  7/2002
Paraguay 2002  Yes  8/2002
Uruguay 2002  No  8/2002
Dominican Republic  2003  No  6/2003
Data were compiled form the Pan American Health Organization (Organización 
Panamericana de la Salud 2005).International Journal of COPD 2008:3(2) 290
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regions, are indispensable instruments to regulate treatments 
and to inﬂ  uence health professionals to be an active part of 
the tobacco cessation process. The guidelines must be based 
on the maximum evidence available and be agreed upon by a 
group of local leaders following a formal and rigorous con-
sensus on methodology. A good example is the Argentinean 
treatment guidelines for tobacco addiction (Ministerio de 
Salud y Ambiente de la Nación 2005), for which planning 
and development were based on the NICE recommendations 
(National Institute of Clinical Excellence) (NICE 2007), and 
on the recommendations of AGREE (Appraisal of the Guide-
lines Research and Evaluation) (The Agree Collaboration 
2001). Their main objectives are to increase the percentage 
of smokers who stop smoking, ensure that all health workers 
have the basic tools to facilitate the process of recovery from 
tobacco dependency, offer basic recommendations based 
upon the best evidence of efﬁ  cacy and cost effectiveness of 
treatments to stop smoking, and adapt the national evidence 
to the local level in order to increase the feasibility and 
applicability of the recommendations.
Brazil, Costa Rica, Mexico, Panama, and Uruguay also 
have national guidelines, and are participating in a project 
to expand Latin American guidelines with the consensus of 
all the nations that comprise the region.
Available pharmacological treatments
Nicotine replacement therapies (NRT) may double the odds 
of successful abstinence from smoking compared to placebo 
(continuous abstinence from 6–12 months, pooled studies 
N = 39,503; odds ratio [OR] = 1.77; 95% conﬁ  dence interval 
[CI]: 1.66–1.88) (Silagy et al 2004). NRT in the form of gums 
and patches are available over the counter in almost all Latin 
American countries. In addition, Mexico has a nicotine oral 
inhalant (Sansores et al 2002). Only in some countries – such 
as Chile, Peru, and Venezuela – is a medical prescription 
necessary to buy NRTs (Organización Panamericana de la 
Salud 2005). Recently, the nasal spray became available in 
Argentina, but only under medical prescription. The most 
commonly observed adverse events (AEs) associated with 
NRTs includes pain in the jaw; gastrointestinal problems, 
hiccoughs, or orodental damage (gum); local skin irritation 
(patch); irritation or burning of the mouth or throat and 
coughing (inhaler); irritated or runny nose (nasal spray) 
(Silagy et al 2004).
A 2 mg box of NRT gum (ie, a 3-day supply) costs 
between US$10 and US$16 in Colombia, Brazil, Uruguay, 
and Argentina (www.kairosweb.com). This price represents 
between 5% and 12% of the minimum salary. A box of 
NRT gum costs the same as 9 packs (of 20 cigarettes) of 
the cheapest brand in Argentina, 10 packs in Uruguay, 12 
in Colombia, and 21 in Brazil (www.kairosweb.com). The 
gap between the price of smoking cessation medication and 
cigarette packs is bigger in Latin America than in Western 
Europe, where medicines are proportionally more accessible 
and cigarettes are signiﬁ  cantly more expensive. The recom-
mended dosing schedules vary by the type of NRT and needs 
of the smokers, but can range from 12 weeks to 6 months or 
more (Pﬁ  zer, Inc 2005a, b; GlaxoSmithKline 2007a).
The medication bupropion is available in practically all 
the countries of the region and always requires a medical 
prescription (Organización Panamericana de la Salud 2005). 
Bupropion approximately doubles the odds of successful 
smoking cessation over placebo at 6 months or greater 
(pooled studies N = 6433; OR = 2.06; 95% CI: 1.77–2.40) 
(Hughes et al 2004). The most commonly observed AEs 
include insomnia, dry mouth, headache, and jitteriness 
(Hughes et al 2004). As an antidepressant drug, bupropion 
is partially ﬁ  nanced by many Latin American public health 
systems or private medical systems and its cost is usually 
lower than NRT. For example, a package of 30 tablets 
(ie, a 15-day supply) costs US$13 in Uruguay and US$18 
in Argentina (www.kairosweb.com). The recommended 
dosing regimen is 150 mg twice daily for 7–12 weeks 
(GlaxoSmithKline 2007b).
The medication varenicline became available beginning 
March/April of 2007 in Uruguay, Mexico, Chile, Brazil, and 
Argentina. Varenicline is the ﬁ  rst non-nicotine pharmaco-
therapy developed for smoking cessation and may triple the 
odds of smoking cessation versus placebo (at 1 year, pooled 
studies N = 1082; OR = 3.22; 95% CI: 2.43–4.27) (Cahill 
et al 2007). The most commonly reported treatment-emergent 
AEs with varenicline are nausea, insomnia, headache, and 
abnormal dreams (Cahill et al 2007). The average cost of 
varenicline is US$57 to US$60 for a 2-week supply (www.
kairosweb.com) and the recommended treatment period is 
12 weeks (Pﬁ  zer, Inc 2007).
Presently, only Brazil and Uruguay have national laws 
to control tobacco consumption and offer free medication as 
part of a public health policy. In Argentina, some Municipal 
Hospitals in Buenos Aires provide free treatments in the clinics 
for smoking cessation. According to the PAHO (www.paho.
org), almost all the Latin American countries have doctor’s 
ofﬁ  ces for smoking cessation, although the coverage is dif-
ferent between countries. Countries such as Brazil, Uruguay, 
Mexico, and Argentina have national tobacco control pro-
grams with speciﬁ  c goals that include health professionals International Journal of COPD 2008:3(2) 291
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with qualiﬁ  cation for smoking cessation treatments. At the 
same time other countries still have not implemented these 
tools.
Drugs for the treatment of tobacco addiction are cost 
effective. It will be the responsibility of the health administra-
tors, public and private, to fund tobacco cessation programs. 
These prevention measures will have a positive impact on 
the health of smokers.
Conclusions
Tobacco consumption is an addiction, accepted worldwide 
as a natural behavior, entrenched in established multi-
cultural bases, propagated by advertising, and encouraged 
as a rapid wealth generator. The tobacco consumption 
problem is complex and involves social, cultural, economic, 
and public health aspects. Fighting the use of tobacco is a 
society’s responsibility, which could be achieved through 
the combined efforts of societal institutions, governments, 
educators, and leaders.
To change the prognosis of the dangers of tobacco in 
the future, certain actions must be taken. These actions 
include: education, at all levels, about the real consequences 
of tobacco consumption; activation of public health policies 
to control tobacco consumption in order to protect minors 
and nonsmokers; commitment of the health professionals in 
general and doctors speciﬁ  cally; and participation of society 
as a whole. This is a pending and inescapable commitment 
for Latin America. Latin American territories have the most 
vulnerable conditions that expose them to the consequences 
of the tobacco epidemic. Latin America encompasses a group 
of countries still in development. In the majority of these 
countries, tobacco plantations are prevalent and tobacco 
products are commercialized (Valdés-Salgado et al 2002; 
Mackay et al 2006). Thus, the tobacco industry exercises 
powerful political inﬂ  uences for tobacco growth, such as 
eluding restrictions and accommodating tobacco production 
(Sebrié et al 2005; Zabert 2006). Smoking has integrated into 
the culture and customs of these countries, most of which are 
just now beginning tobacco control policies.
The harm caused by the tobacco consumption, the addic-
tive characteristics of the disease, and the consequences of 
environmental tobacco smoke have spread greatly just in 
the last few years. Smoking tobacco is cheap and therefore 
within reach of almost all of the Latin American population. 
Health professionals also exhibit similar demographics of 
tobacco consumption to the population that they should 
help. They are generally poorly educated and trained on the 
topic, lacking knowledge about the prescribing and utility 
of available smoking cessation pharmacological treatments 
(Noble et al 1996; Mirra and Rosemberg 1997a; Minervini 
et al 1998; Rondelli et al 1999; Zabert et al 1999; Zabert et al 
2002; Sánchez and Lisanti 2003; Bello et al 2004; Ferrero 
et al 2004; Monreal et al 2004; Zabert and Verra 2004; Anon 
2005b; Organización Panamericana de la Salud 2005; Müller 
and Zabert 2005; Mackay et al 2006; Minervini et al 2006; 
Zabert 2006).
Considering these conditions, it can be speculated 
that tobacco consumption in Latin America will continue 
increasing in the future, especially affecting women and 
young people. However, the emergence of control policies, 
expansion of knowledge, and new therapeutic possibilities 
inspire hope. Therefore, all action towards tobacco control 
is anticipated and welcome. The commitment to the FCTC, 
the policies for tobacco control, and the creation of health 
reforms supporting and promoting tobacco cessation will be 
instruments of extraordinary value in this ﬁ  ght. For Latin 
America, it is urgent to educate health professionals to be 
part of the tobacco cessation effort, so that – with the arrival 
of new drugs and the application of better strategies adapted 
to their customs – more patients can stop smoking.
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